BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $30 from $33 and keeps a Buy rating on the shares. The firm updated its model for fiscal Q1 financials, calling the quarterly update “mainly a reiteration of timelines for key R&D programs.” Following the update, the firm pushed back the MG and CIDP launches to 2027-plus to reflect 1402 trial timelines, the analyst noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Immunovant price target lowered to $37 from $40 at JPMorgan
- Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
- Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
- Immunovant Reports Progress and Financial Results
- Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating